시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 부데소니드(Budesonide) 시장 보고서(2025년)
Budesonide Global Market Report 2025
상품코드 : 1815879
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

부데소니드 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 6.0%를 나타낼 것으로 예측되고 129억 5,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 효과적인 치료법에 대한 수요 증가, 새로운 약물 전달 시스템 개발, 부데소니드 사용 증가, 천식에 취약한 노인 인구 증가, 그리고 제네릭 부데소니드 제품 확대로 인한 것으로 분석됩니다. 예측 기간의 주요 트렌드로는 생물학적 제제 및 바이오시밀러 채택, 약물 전달 시스템 발전, 신규 제형에 대한 규제 승인, 새로운 약물 전달 시스템 개발, 그리고 기술 발전 등이 포함됩니다.

향후 5년간 6.0% 성장률 전망은 해당 시장에 대한 이전 추정치 대비 0.4% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 부과 영향 때문입니다. 관세 부과로 인해 독일 및 스웨덴에서 수입되는 부데소니드 비강 스프레이의 비용이 증가하여 미국 알레르기 치료 센터에 상당한 도전 과제가 될 수 있으며, 이는 천식 관리 감소 및 면역학 치료 비용 증가로 이어질 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 증가로 인한 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더 광범위하게 나타날 것입니다.

호흡기 질환의 유병률 증가가 부데소니드 시장 성장을 주도할 것으로 예상됩니다. 가스 교환을 담당하는 기관과 조직에 영향을 미치는 호흡기 질환은 대기 오염 증가, 미세먼지 노출, 알레르겐 등 요인으로 인해 증가하고 있습니다. 이러한 환경적 요인은 천식 및 만성 폐쇄성 폐질환(COPD)과 같은 질환에 크게 기여합니다. 코르티코스테로이드인 부데소니드는 염증을 감소시키고 공기 흐름을 개선하며 천명음 및 호흡곤란과 같은 증상을 예방함으로써 이러한 호흡기 질환 관리에 일반적으로 사용됩니다. 예를 들어, 미국 국립보건통계센터(NCHS)에 따르면 미국 성인 천식 유병률은 2021년 8.4%에서 2022년 8.7%로 증가했으며, 같은 기간 천식 발작 발생률은 3.3%에서 3.7%로 상승했습니다. 결과적으로 호흡기 질환 발생률 증가가 부데소니드 시장 확장을 촉진할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Budesonide is a corticosteroid medication used to reduce inflammation in conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (including Crohn's disease and ulcerative colitis), and allergic rhinitis. It functions by suppressing the immune response and reducing inflammation in the airways or digestive tract.

The primary forms of budesonide include inhalation powder, aerosols, injectable suspensions, tablets, and capsules. Inhalation budesonide powder is a corticosteroid delivered via a dry powder inhaler to reduce airway inflammation in respiratory conditions. Budesonide is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used for various applications, including the treatment of nasal diseases, inflammatory bowel diseases, respiratory diseases, and other conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The budesonide market research report is one of a series of new reports from The Business Research Company that provides budesonide market statistics, including the budesonide industry global market size, regional shares, competitors with the budesonide market share, detailed budesonide market segments, market trends, and opportunities, and any further data you may need to thrive in the budesonide industry. This budesonide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The budesonide market size has grown strongly in recent years. It will grow from $9.72 billion in 2024 to $10.26 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the rising prevalence of respiratory diseases, increased awareness about inhaled corticosteroids, the introduction of budesonide-based combination therapies, the expansion of healthcare access and infrastructures, and the adoption of budesonide for off-label use in inflammatory bowel diseases.

The budesonide market size is expected to see strong growth in the next few years. It will grow to $12.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing demand for effective treatments, development of novel drug delivery systems, increasing use of budesonide, rising geriatric population prone to asthma, and expansion of generic budesonide products. Major trends in the forecast period include the adoption of biologics and biosimilars, advancements in drug delivery systems, regulatory approvals for new formulations, the development of novel drug delivery systems, and technological development.

The forecast of 6.0% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. allergy treatment centers by increasing costs of budesonide nasal sprays imported from Germany and Sweden, potentially reducing asthma control and raising immunology treatment expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of respiratory diseases is expected to drive the growth of the budesonide market. Respiratory diseases, which impact the organs and tissues responsible for gas exchange, are increasing due to factors such as rising air pollution, exposure to particulate matter, and allergens. These environmental factors contribute significantly to conditions such as asthma and chronic obstructive pulmonary disease (COPD). Budesonide, a corticosteroid, is commonly used to manage these respiratory diseases by reducing inflammation, improving airflow, and preventing symptoms such as wheezing and shortness of breath. For instance, according to the National Center for Health Statistics (NCHS), the prevalence of asthma among adults in the U.S. increased from 8.4% in 2021 to 8.7% in 2022, with asthma episodes rising from 3.3% to 3.7% during the same period. Consequently, the growing incidence of respiratory diseases is expected to fuel the expansion of the budesonide market.

Companies in the budesonide market are focusing on innovative oral and inhaled therapies to enhance treatment effectiveness and patient adherence. Oral formulations of budesonide provide a convenient treatment option, especially for inflammatory conditions. For example, in February 2024, Takeda Pharmaceuticals received FDA approval for EOHILIA, the first and only FDA-approved oral budesonide suspension for patients aged 11 and above with eosinophilic esophagitis (EoE). This approval was based on positive efficacy and safety data from clinical trials, demonstrating the potential of oral budesonide in expanding treatment options for respiratory and inflammatory diseases.

In March 2023, Cheplapharm Arzneimittel GmbH acquired the U.S. commercial rights for PULMICORT FLEXHALER from AstraZeneca. This acquisition allows Cheplapharm to diversify its product offerings and expand its presence in the U.S. pharmaceutical market while ensuring continued availability of PULMICORT FLEXHALER, a widely used budesonide-based asthma treatment. AstraZeneca, a UK-based biopharmaceutical company, has long been a key player in developing and marketing PULMICORT for respiratory conditions such as asthma and COPD.

Major players in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, and Shanghai Sine Promod Pharmaceutical Co. Ltd.

North America was the largest region in the budesonide market in 2024. The regions covered in budesonide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the budesonide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The budesonide market consists of sales of nebulizer suspension, inhalers, and nasal sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Budesonide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on budesonide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for budesonide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The budesonide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Budesonide Market Characteristics

3. Budesonide Market Trends And Strategies

4. Budesonide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Budesonide Growth Analysis And Strategic Analysis Framework

6. Budesonide Market Segmentation

7. Budesonide Market Regional And Country Analysis

8. Asia-Pacific Budesonide Market

9. China Budesonide Market

10. India Budesonide Market

11. Japan Budesonide Market

12. Australia Budesonide Market

13. Indonesia Budesonide Market

14. South Korea Budesonide Market

15. Western Europe Budesonide Market

16. UK Budesonide Market

17. Germany Budesonide Market

18. France Budesonide Market

19. Italy Budesonide Market

20. Spain Budesonide Market

21. Eastern Europe Budesonide Market

22. Russia Budesonide Market

23. North America Budesonide Market

24. USA Budesonide Market

25. Canada Budesonide Market

26. South America Budesonide Market

27. Brazil Budesonide Market

28. Middle East Budesonide Market

29. Africa Budesonide Market

30. Budesonide Market Competitive Landscape And Company Profiles

31. Budesonide Market Other Major And Innovative Companies

32. Global Budesonide Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Budesonide Market

34. Recent Developments In The Budesonide Market

35. Budesonide Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기